Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.69 |
| ▸ | NAAA | Q02083 | 1/20 | 0.65 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.56 |
| ▸ | FAAH | O00519 | 3/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889214 | 1.00 | CASP2 (0.69) | CASP2NAAAEPHX1FAAHCNR1 | |
| SCHEMBL889205 | 1.00 | CASP2 (0.69) | CASP2NAAAEPHX1FAAHCNR1 | |
| SCHEMBL889167 | 1.00 | CASP2 (0.69) | CASP2NAAAEPHX1FAAHCNR1 | |
| SCHEMBL889213 | 1.00 | CASP2 (0.69) | CASP2NAAAEPHX1FAAHCNR1 | |
| SCHEMBL889156 | 1.00 | CASP2 (0.69) | CASP2NAAAEPHX1FAAHCNR1 | |
| SCHEMBL889294 | 1.00 | CASP2 (0.69) | CASP2NAAAEPHX1FAAHCNR1 | |
| SCHEMBL24393473 | 1.00 | CASP2 (0.69) | CASP2NAAAEPHX1FAAHCNR1 | |
| SCHEMBL889206 | 1.00 | CASP2 (0.69) | CASP2NAAAEPHX1FAAHCNR1 | |
| SCHEMBL889286 | 1.00 | CASP2 (0.69) | CASP2NAAAEPHX1FAAHCNR1 | |
| SCHEMBL28342490 | 1.00 | CASP2 (0.69) | CASP2NAAAEPHX1FAAHCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160009657-A1 | AMINE-CONTAINING LIPIDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-01-14 | — | — | US | disclosed |
| US-9006487-B2 | Amine-containing lipids and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-04-14 | — | — | US | disclosed |
| EP-2476756-A1 | Amine-containing lipids and uses thereof | Massachusetts Institute of Technology (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2011-03-03 | — | — | US | disclosed |
| US-20110009641-A1 | Amine-containing lipids and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
| WO-2009097332-A2 | THERAPEUTIC COMPOSITIONS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | FCGRT, MYD88, C3AR1 | CASP2 2840/4885NAAA 789/4885EPHX1 2839/4885 |
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | PHOSPHO1, SGMS1, APOB | CASP2 1497/4885NAAA 625/4885EPHX1 1570/4885 |
| US-20110009641-A1 | Amine-containing lipids and uses thereof | PHOSPHO1, CHMP4B, SGMS1 | CASP2 3638/4885NAAA 78/4885EPHX1 914/4885 |
| US-20160009657-A1 | AMINE-CONTAINING LIPIDS AND USES THEREOF | PHOSPHO1, CHMP4B, SGMS1 | CASP2 3638/4885NAAA 78/4885EPHX1 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.